BREAKING NEWS
[NOVEMBER 12, 2026] - On November 9, the U.S. Food and Drug Administration (FDA) announced new safety labeling requirements for glucagon-like peptide-1 receptor agonists (GLP-1 RAs), citing a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare but serious condition that can cause sudden, painless vision loss, sometimes permanently. The agency recommends that healthcare providers inform patients taking these medications about this potential risk.
In his 2025 book, The Quantum Power of GLP-1 Peptides (SSRP Publications), Dr. William Seeds addressed emerging research suggesting a possible association between GLP-1 RAs and NAION. Although the reported cases were rare, he emphasized the importance of continued monitoring. He also noted that underlying vascular problems, particularly in individuals with obesity or other metabolic risk factors, may contribute to stress on the retina and optic nerve, potentially increasing susceptibility to vision-related complications.
The FDA's announcement references a 2024 study published in JAMA Ophthalmology, "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide." Although the agency identified several limitations in the study, it determined that further investigation was warranted and undertook a comprehensive review of clinical trial data, animal studies, observational research, and postmarketing reports.
As part of its evaluation, the FDA conducted a meta-analysis of 126 randomized clinical trials involving more than 134,000 participants. The analysis found 6.4 NAION events per 100,000 person-years among patients taking GLP-1 RAs, compared with 3.8 events per 100,000 person-years among patients receiving placebo or other non-GLP-1 RA glucose-lowering medications. While these findings suggest a potential increased risk, they also underscore how rare NAION remains.
Based on its review, the FDA concluded that GLP-1 RAs may be associated with an increased risk of rare NAION events and is requiring manufacturers to add information about this potential risk to the Warnings and Precautions section of prescribing information for all GLP-1 RAs.
The agency also recommends that healthcare providers advise patients to report sudden, painless vision loss, blind spots, or other visual disturbances immediately. Patients with suspected NAION should be promptly referred to an ophthalmologist for evaluation. For patients who develop NAION, clinicians should consider discontinuing GLP-1 RA therapy unless the benefits clearly outweigh the risks.
The announcement reinforces the importance of ongoing safety surveillance, individualized risk assessment, and patient education as the clinical use of GLP-1 receptor agonists continues to expand.
Read the Full Announcement
For further details, please refer to:
https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
For future updates like this, education, training, and support, explore what the SSRP Community has to offer.
Sources:
- U.S. Food and Drug Administration. FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition. November 9, 2026.
- Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024;142(8):732–739. doi:10.1001/jamaophthalmol.2024.2296.